We thank Drs Noubiap and Kamtchum-Tatuene for their comments on our article. They express their concerns about the safety of short-term treatment with high-dose paracetamol, question whether the high dose of paracetamol used in PAIS 2 (Paracetamol [Acetaminophen] in Stroke 2) leads to a larger temperature reduction than a standard dose, and consider a new, larger, clinical trial of fever prevention in stroke futile. Their concerns can fortunately be refuted. [...]

Additional Metadata
Persistent URL dx.doi.org/10.1161/STROKEAHA.117.017612, hdl.handle.net/1765/100549
Journal Stroke
Rights No subscription
Citation
de Ridder, I, Dippel, D.W.J, & van der Worp, B. (2017). Response by de Ridder et al to Letter Regarding Article, “PAIS 2 (Paracetamol [Acetaminophen] in Stroke 2) Results of a Randomized, Double-Blind Placebo-Controlled Clinical Trial”. Stroke. doi:10.1161/STROKEAHA.117.017612